Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer

Abstract Patients with early-stage, hormone receptor–positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of distant recurrence up to 15 years following 5 years o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brock Schroeder, Yi Zhang, Olle Stål, Tommy Fornander, Adam Brufsky, Dennis C. Sgroi, Catherine A. Schnabel
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/92e90599335f479b9f2cb277f9642bd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92e90599335f479b9f2cb277f9642bd4
record_format	dspace
spelling	oai:doaj.org-article:92e90599335f479b9f2cb277f9642bd42021-12-02T16:19:49ZRisk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer10.1038/s41523-017-0037-32374-4677https://doaj.org/article/92e90599335f479b9f2cb277f9642bd42017-08-01T00:00:00Zhttps://doi.org/10.1038/s41523-017-0037-3https://doaj.org/toc/2374-4677Abstract Patients with early-stage, hormone receptor–positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of distant recurrence up to 15 years following 5 years of endocrine therapy, highlighting the need for further stratification based on individualized risk to select patients for extended endocrine therapy. In this study, the incremental utility of genomic classification to stratify clinically low-risk patients for late distant recurrence was evaluated using the Breast Cancer Index. In 547 T1N0 patients from two cohorts that were disease-free at 5 years post-diagnosis, Breast Cancer Index categorized 32 and 36% from each cohort, respectively, with high risk of late distant recurrence that was associated with significantly reduced distant recurrence-free survival (86.7 and 89.6%) between years 5–15 and 5–10 compared to Breast Cancer Index low risk (95.4%; P = 0.0263 and 98.4%; P = 0.008). Findings support consideration of genomic classification in clinically low-risk hormone receptor–positive patients to identify candidates for extended endocrine therapy.Brock SchroederYi ZhangOlle StålTommy FornanderAdam BrufskyDennis C. SgroiCatherine A. SchnabelNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-3 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Brock Schroeder Yi Zhang Olle Stål Tommy Fornander Adam Brufsky Dennis C. Sgroi Catherine A. Schnabel Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
description	Abstract Patients with early-stage, hormone receptor–positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of distant recurrence up to 15 years following 5 years of endocrine therapy, highlighting the need for further stratification based on individualized risk to select patients for extended endocrine therapy. In this study, the incremental utility of genomic classification to stratify clinically low-risk patients for late distant recurrence was evaluated using the Breast Cancer Index. In 547 T1N0 patients from two cohorts that were disease-free at 5 years post-diagnosis, Breast Cancer Index categorized 32 and 36% from each cohort, respectively, with high risk of late distant recurrence that was associated with significantly reduced distant recurrence-free survival (86.7 and 89.6%) between years 5–15 and 5–10 compared to Breast Cancer Index low risk (95.4%; P = 0.0263 and 98.4%; P = 0.008). Findings support consideration of genomic classification in clinically low-risk hormone receptor–positive patients to identify candidates for extended endocrine therapy.
format	article
author	Brock Schroeder Yi Zhang Olle Stål Tommy Fornander Adam Brufsky Dennis C. Sgroi Catherine A. Schnabel
author_facet	Brock Schroeder Yi Zhang Olle Stål Tommy Fornander Adam Brufsky Dennis C. Sgroi Catherine A. Schnabel
author_sort	Brock Schroeder
title	Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
title_short	Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
title_full	Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
title_fullStr	Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
title_full_unstemmed	Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
title_sort	risk stratification with breast cancer index for late distant recurrence in patients with clinically low-risk (t1n0) estrogen receptor-positive breast cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/92e90599335f479b9f2cb277f9642bd4
work_keys_str_mv	AT brockschroeder riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT yizhang riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT ollestal riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT tommyfornander riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT adambrufsky riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT denniscsgroi riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT catherineaschnabel riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer
_version_	1718384185010290688

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer

Ejemplares similares